Drugs Made In America Acquisition Corp Units
DMAAU
15 hedge funds and large institutions have $33.4M invested in Drugs Made In America Acquisition Corp Units in 2025 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
14.28% more ownership
Funds ownership: 0% → 14.28% (+14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Heights Capital Management
San Francisco,
California
|
+$6.56M |
| 2 |
Boothbay Fund Management
New York
|
+$6.09M |
| 3 |
Westchester Capital Management (New York)
Valhalla,
New York
|
+$5.05M |
| 4 |
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$4.24M |
| 5 |
Context Capital Management
Lajolla,
California
|
+$2.52M |
Top Sellers
DMAAU Hedge Fund Activity: Q1 2025 in Review
15 of the 7,486 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Units (DMAAU) for Q1 2025, worth a combined $33.4M.
Buyers outnumbered sellers: 15 funds opened new DMAAU positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Heights Capital Management, opening a new position worth an estimated $6.56M.
- 15 institutional investors held Drugs Made In America Acquisition Corp Units (DMAAU) as of Q1 2025, up from 0 in Q4 2024.
- Funds reported $33.4M of Drugs Made In America Acquisition Corp Units stock for Q1 2025.
- 15 funds opened new Drugs Made In America Acquisition Corp Units positions in Q1 2025 and 0 closed out, a net change of +15 holders.
- The largest Drugs Made In America Acquisition Corp Units buyer in Q1 2025 was Heights Capital Management, an estimated $6.56M added.
Based on aggregated 13F filings for Q1 2025.